Greer concluded, in a study published in the September 20, 2006 issue of the American Journal of Respiratory Critical Care Medicine, that CX546, "effectively reverses opioid- and barbiturate-induced respiratory depression without reversing the analgesic response."
"These results open up the real possibility of combining an ampakine compound with commonly prescribed barbiturates or opiates to reduce the likelihood that life-threatening respiratory depression will occur," noted explained Roger G. Stoll, Ph.D., Chairman, President, and CEO of Cortex.
Cortex Pharmaceuticals has entered into a Patent Licensing Agreement with the University of Alberta for this new respiratory application for the use of AMPAKINE compounds. Under terms of the license Cortex will evaluate a number of novel low and high impact AMPAKINE compounds for a range of new respiratory applications, such as, respiratory depression induced by opiates and barbiturates to start and others to be named at a future time. In return, Cortex will provide the University with an undisclosed upfront payment, milestone compensation, and royalties from the commercialization of specific AMPAKINE drugs approved for any therapeutic and/or prophylactic indication associated with respiratory depression . Dr. Greer, who has successfully filed a patent for the use of AMPAKINE drugs for these respiratory indications, will receive multiple years of research support funding from Cortex.
Cortex focuses on novel drug therapies for neurological and psychiatric disorders. Its le
'"/>
Contact: Mark Varney
mvarney@cortexpharm.com
949-231-0672
Cortex Pharmaceuticals
4-Jun-2007